EXODIAB – strategic research
Researchers at LUDC are part of EXODIAB (Excellence of Diabetes Research in Sweden), a strategic research area at Lund University. The aim of EXODIAB is to develop new treatments and drugs to prevent or cure diabetes.
The primary aim of EXODIAB is to develop new treatments and drugs that can prevent, delay, or cure diabetes and its complications. A second objective is to create improved conditions for the personalisation of care and treatment of patients with diabetes.
Platforms for collaboration
EXODIAB is a joint strategic research initiative in the diabetes area at Lund University and Uppsala University, and at LUDC more than 300 members of staff are involved in this collaborative effort.
The strategic research area integrates research in various fields with clinical studies and population studies (epidemiology) and creates platforms for collaboration between academia and industry.
EXODIAB is funded by a strategic research grant from the Swedish Research Council.
Link to a list of research output in Lund University’s research portal
Link to a list of projects within EXODIAB in Lund University’s research portal
Contact
Allan Vaag
Professor and Coordinator of LUDC and EXODIAB
allan [dot] vaag [at] med [dot] lu [dot] se
Lena Eliasson
Professor and Vice Coordinator of LUDC and EXODIAB
lena [dot] eliasson [at] med [dot] lu [dot] se
+46 (0)40 39 11 53
+46 (0)70 522 54 14